Targeted Killing of Virally Infected Cells by Radiolabeled Antibodies to Viral Proteins
Figure 3
RIT of SCID Mice Injected Intrasplenically with HIV-1JR-CSF-Infected Human PBMCs with 188Re- and 213Bi-Labeled Human Anti-gp41 mAb 246-D
(A) Mice were treated IP 1 h after infection with infected hPBMCs with either 20 μg of cold 246-D (n = 4); 100 μCi (3.7 MBq) (20 μg) of 213Bi-1418 (n = 5) or 80 μCi (2.96 MBq) (20 μg) of 188Re-1418 (n = 3) as isotype-matching controls; 80 μCi (2.96 MBq) (20 μg) of 188Re-246-D (n = 4); or 100 μCi (3.7 MBq) (20 μg) of 213Bi-246-D (n = 5). One group was left untreated (n = 4). Another group of mice were given 80 μCi (2.96 MBq) (20 μg) of 188Re-246-D IP 1 h before infection with infected hPBMCs (n = 4).
(B) Mice were injected IP with 188Re-246-D (20 μg) with activity of 40 μCi (1.48 MBq) (n = 4), with 160 μCi (5.92 MBq) (n = 4), or with 20 μg of cold 246-D (n = 4). A fourth group was untreated (n = 4). The number of HIV-1-infected hPBMCs in the spleens were then determined by limiting dilution coculture and presented as TCID50/106 splenocytes. Each bar represents the mean of TCID50/106 splenocytes in a given group of mice, and error bars show standard error of the mean.